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Severe acquired von Willebrand syndrome secondary to 
systemic lupus erythematosus
Dear	Editor,
The	acquired	von	Willebrand	syndrome	(AVWS)	is	a	rare	bleeding	dis‐
order	that	mimics	the	clinical	and	laboratory	findings	of	inherited	von	
Willebrand	disease	(VWD)	but	occurs	in	individuals	with	no	previous	
personal	or	family	history	of	bleeding.	The	main	pathogenic	mecha‐
nism	is	the	accelerated	removal	of	von	Willebrand	factor	(VWF)	from	
plasma,	 due	 to	 different	 causes	 such	 as	 the	 increased	 proteolytic	
degradation	of	VWF,	its	adsorption	onto	malignant	cells	or	activated	
platelets	or	 to	 immunoglobulins	against	 the	VWF‐factor	VIII	 (FVIII)	
complex.1	The	syndrome	is	associated	with	lymphoproliferative,	my‐
eloproliferative,	cardiovascular	and	autoimmune	diseases	and	cancer,	
and	is	more	often	occurring	in	the	elderly.2	The	first	case	of	AVWS	
secondary	 to	 systemic	 lupus	erythematosus	 (SLE)	was	 reported	by	
Simone	et al3	 in	1968.	Although	this	association	 is	 infrequently	de‐
scribed	 in	 literature,1,3,4	 even	 less	 frequent	 is	 its	presentation	with	
clinical	 and	 laboratory	 features	 resembling	 a	 severe	 VWD	 pheno‐
type.5	Most	 cases	 have	mild	 to	moderate	 bleeding	 tendency,	with	
laboratory	characteristics	similar	to	inherited	VWD	type	1.1,6,7
The	differential	 diagnosis	 between	AVWS	and	VWD	might	 be	
difficult	because	the	personal	history	of	bleeding	(acquired	or	 life‐
long)	 is	 not	 always	 conclusive	 and	 the	 two	 diseases	 share	 similar	
laboratory	 results.	 A	 potential	 diagnostic	 biomarker,	 the	 ratio	 of	
the	VWF	propeptide	(VWFpp)	to	VWF	antigen	(VWF:Ag)	(VWFpp/
VWF:Ag),	 is	 an	 indicator	of	 an	enhanced	VWF	clearance.8‐10 Only 
20%	of	patients	with	AVWS	have	autoantibodies	inactivating	VWF	
activity,	indicating	that	mixing	tests	such	as	the	Bethesda	assay	may	
be	often	inadequate	to	detect	antibodies.11	A	tool	that	might	be	use‐
ful	 to	confirm	the	 laboratory	diagnosis	of	AVWS	 is	 the	ELISA	that	
detects	anti‐VWF	non‐neutralizing	antibodies.11	Here,	we	report	the	
case	of	a	severe	AVWS	secondary	to	a	previously	undiagnosed	SLE,	
the	main	laboratory	features	over	time	and	the	positive	clinical	and	
laboratory	effect	of	immunosuppressive	therapy.	The	patient	was	a	
19	years	old	girl	admitted	to	the	emergency	room	with	spontaneous	
gum	bleeding	and	general	malaise.	The	initial	laboratory	evaluation	
showed	 a	 prolonged	 activated	partial	 thromboplastin	 time	 (aPTT),	
with	 a	 ratio	 of	 1.51	 (normal	 range	 0.86‐1.20).	 Haemoglobin	 was	
10.3	g/dL	 (normal	 range	 12.0‐16.0	g/dL),	 platelet	 count	 147	000/
μL	(normal	range	130	000‐400	000/μL),	aspartate	aminotransferase	
47	U/L	(normal	range	10‐33	U/L),	alanine	aminotransferase	108	U/L	
(normal	range	6‐41	U/L).	The	day	after	admission,	the	patients	also	
declared	to	have	suffered	 in	the	most	recent	past	of	easy	bruising	
and	 heavy	 menstrual	 bleeding,	 but	 she	 had	 no	 lifelong	 personal	
and	family	history	of	bleeding.	The	laboratory	assessment	revealed	
a	pattern	resembling	a	severe	form	of	VWD,	with	very	low	plasma	
values	 of	 factor	VIII	 (FVIII),	 VWF:Ag,	VWF	 ristocetin	 cofactor	 ac‐
tivity	 (VWF:RCo)	 (Table	1,	Baseline)	 and	a	barely	detectable	VWF	
multimeric	 pattern.	 The	 tests	 for	 hepatitis	 C	 and	 B	 viruses	 were	
negative.	 Since	 the	 patient	 reported	 a	 significant	 bleeding	 history	
only	in	recent	times,	an	AVWS	was	hypothesized	and	the	laboratory	
evaluation	was	guided	by	this	hypothesis.	At	baseline	the	VWFpp/
VWF:Ag	 was	 54	 (normal	 range	 0.6‐1.6),	 indicating	 a	 normal	 pro‐
VWF	synthesis	but	 a	markedly	 increased	plasma	clearance	of	 this	
moiety,	as	typical	of	AVWS.	Mixing	test	with	the	Bethesda	method,	
using	 the	VWF:RCo	and	VWF:CB	assays,	 showed	 the	presence	of	
a	 mild	 inhibitor	 against	 VWF:RCo	 (1	 BU).The	 syndrome	was	 con‐
firmed	 by	 the	 normal	 intraplatelet	 VWF	 content,	 but	 the	 ELISA	
for	anti‐VWF	antibodies	demonstrated	a	high	titre	of	 IgG	and	also	
the	 presence	 of	 IgM	 (Table	 1).	 Further	 laboratory	 investigations	
revealed	 the	 presence	 of	 high	 titre	 antinuclear	 antibody	 (1:1280,	
normal	value	<1:60),	anti‐native	DNA	antibody	(1:40,	normal	value	
<1:10)	and	anti‐double‐stranded	DNA	antibody	(311	IU/mL,	normal	
range	0‐27),	some	consumption	of	the	complement	fractions	C3	and	
C4,	mild	anaemia	and	thrombocytopenia.	Because	these	laboratory	
findings,	together	with	other	clinical	manifestations	such	as	muscle	
and	joint	pain,	led	to	a	novel	diagnosis	of	SLE,	she	started	an	immu‐
nosuppressive	daily	treatment	with	prednisone	50	mg,	azathioprine	
100	mg	and	hydroxychloroquine	sulphate	200	mg.	After	2	weeks,	a	
progressive	increase	in	FVIII	and	VWF	values	with	concomitant	re‐
duction	in	the	titre	of	anti‐VWF	IgG/IgM	antibodies	was	observed.	
At	 the	follow‐up	 (FU)	day	168	the	patient	showed	a	normalization	
of	FVIII	and	VWF	values,	and	the	anti‐VWF	IgG	and	IgM	antibodies	
titre	became	undetectable	(Table).	The	titre	of	anti‐double‐stranded	
DNA	antibody	decreased	from	311	to	55	IU/mL	and	the	C3	and	C4	
complement	 fraction	 and	 beta2‐microglobulin	 became	 normal.	 A	
possible	explanation	of	an	AVWS	secondary	to	SLE	is	the	increased	
VWF	clearance	due	to	an	anti‐VWF	antibody.	The	enhanced	VWF	
clearance	 in	our	patient	was	confirmed	by	 the	markedly	 increased	
VWFpp/VWF:Ag	 values.	 By	 following	 up	 the	 patient	 over	 time,	 a	
decrease	in	the	VWFpp/VWF:Ag	was	observed,	along	with	the	nor‐
malization	of	VWF	measurements	that	occurred	one	month	after	the	
beginning	of	the	immunosuppressive	therapy.	The	baseline	results	of	
the	VWFpp/VWF:Ag	measurement	facilitated	the	differential	diag‐
nosis	between	VWD	and	AVWS,	and	evaluation	over	time	confirmed	
the	efficacy	of	the	immunological	treatment	and	the	remission	of	the	
underlying	disease,	previously	undiagnosed.12	It	has	been	already	re‐
ported	that	the	eradication	of	the	autoantibodies	with	an	aggressive	
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immunosuppression	 therapy	 is	 critical	 for	 the	 treatment	of	under‐
lying	autoimmune	disorders,1	as	confirmed	herewith.	In	this	patient	
mixing	 tests	 revealed	 a	 neutralizing	 antibody	 at	 a	 low	 titre	 (1BU),	
but	high	titre	ant‐VWF	IgG	and	IgM	were	shown	by	the	ELISA	assay.
In	conclusion,	we	described	herein	a	rare	case	of	severe	AVWS	
secondary	to	SLE.	When	the	differential	diagnosis	between	AVWS	
and	VWD	is	challenging,	the	use	of	VWFpp/VWF:Ag	and	the	ELISA	
for	the	detection	of	anti‐VWF	antibodies	may	facilitate	the	diagno‐
sis.	Also,	 the	 successful	 treatment	points	out	 the	 importance	of	 a	
therapy	aimed	at	resolving	the	underlying	disease	and	therefore	the	
acquired	bleeding	syndrome.
ACKNOWLEDG EMENTS
The	authors	would	like	to	thank	Prof.	P.	M.	Mannucci	for	his	critical	
advice.
DISCLOSURE S
FP	has	received	honoraria	for	participating	as	a	speaker	at	satellite	
symposia	 and	 educational	 meetings	 organized	 by	 Ablynx,	 Grifols,	
Sobi,	Shire,	F.	Hoffmann‐La	Roche	and	Alnylam.	She	is	recipient	of	
research	 grant	 funding	 from	 Ablynx,	 Novo	 Nordisk,	 Kedrion	 and	
Biokit	paid	to	Fondazione	Luigi	Villa,	and	she	has	received	consulting	
fees	from	Kedrion	and	LFB.	She	is	also	member	of	the	scientific	ad‐
visory	boards	of	Ablynx,	F.	Hoffmann‐La	Roche	and	Shire.	The	other	
authors	stated	that	they	had	no	interests	which	might	be	perceived	
as	posing	a	conflict	or	bias.
AUTHOR CONTRIBUTION
FS	and	LB	wrote	the	manuscript.	PC	performed	the	assays.	MC	col‐
lected	 clinical	 data.	 EB	 and	 FP	 discussed	 the	 results	 and	 critically	
revised	the	manuscript.
ORCID
Francesca Stufano  http://orcid.org/0000‐0001‐5214‐0580 
Flora Peyvandi  http://orcid.org/0000‐0001‐7423‐9864 
Francesca	Stufano1
Luciano	Baronciani1
Eugenia	Biguzzi1
Giovanna	Cozzi1
Paola	Colpani1
Marta	Chisini1
Flora	Peyvandi1,2
1Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and 
Fondazione Luigi Villa, Fondazione IRCCS Ca’ Granda Ospedale 
Maggiore Policlinico, Milan, Italy
2Department of Pathophysiology and Transplantation, Università degli 
Studi di Milano, Milan, Italy
Correspondence
Flora Peyvandi, Angelo Bianchi Bonomi Hemophilia and Thrombosis 
Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 
Milan, Italy.
Email: flora.peyvandi@unimi.it
R E FE R E N C E S
	 1.	 Franchini	M,	Lippi	G.	Favaloro	EJ.	Advances	in	hematology.	Etiology	
and	 diagnosis	 of	 acquired	 von	 Willebrand	 syndrome.	 Clin Adv 
Hematol Oncol.	2010;8:20‐24.
	 2.	 Federici	AB,	Rand	JH,	Bucciarelli	P	et	al.	Acquired	von	Willebrand	
syndrome:	 data	 from	 an	 international	 registry.	 Thromb Haemost. 
2000;84:345‐349.
	 3.	 Simone	JV,	Cornet	JA,	Abildgaard	CF.	Acquired	von	Willebrand's	syn‐
drome	in	systemic	lupus	erythematosus.	Blood. 1968;31:806‐812.
	 4.	 Taveras	AS,	Alexis	K,	Sridharan	A	et	al.	Acquired	Von	Willebrand's	
syndrome	 in	 systemic	 lupus	 erythematosus.	 Case Rep Hematol. 
2014;2014:208597.
TA B L E  1  Laboratory	assessment
Days of FU FVIII:C, IU/dL VWF:Ag, IU/dL VWF:RCo, IU/dL VWF:CB, IU/dL VWFpp/VWF:Ag
Anti‐VWF IgG 
titration
Anti‐VWF 
IgM 
titration
Baseline 3 2 0.5b <1 54 1:640 1:40
50a 10 3 0.5b NT 60 1:1280 1:80
62 36 12 13 NT 9.4 1:640 1:20
78 149 73 71 73 2.05 1:160 1:20
125 190 123 122 161 1.17 1:40 <1:20
168 118 70 63 NT NT <1:20 <1:20
Normal	range 50‐147 40‐169c 
55‐165d
41‐160c 
53‐168d
45‐170c 
56‐174d
0.6‐1.6 <1:20 <1:20
BU,	Bethesda	Unit;	FU,	follow‐up;	FVIII:C,	FVIII	coagulant	activity;	IU,	International	Unit;	NT,	not	tested;	VWF,	von	Willebrand	factor;	VWF:Ag,	VWF	
antigen;	VWF:CB,	VWF	collagen	binding;	VWF:RCo,	VWF	ristocetin	cofactor	activity;	VWFpp/VWF:Ag,	VWFpp	to	VWF:Ag	ratio.
aImmunosuppressive	therapy	started	at	day	45;	
bchemiluminescent	based	assay;	
cO	blood	group;	
dnon‐O	blood	group.	
e32  |     LETTERS TO THE EDITOR
	 5.	 Gavva	C,	Patel	P,	Shen	YM,	Frenkel	E,	Sarode	R.	A	case	of	 auto‐
immune	 severe	 acquired	 von	Willebrand	 syndrome	 (type	 3‐like).	
Transfus Apher Sci.	2017;56:431‐433.
	 6.	 Michiels	JJ,	Berneman	Z,	Gadisseur	A	et	al.	Immune‐mediated	eti‐
ology	of	acquired	von	Willebrand	syndrome	 in	systemic	 lupus	er‐
ythematosus	and	 in	benign	monoclonal	gammopathy:	 therapeutic	
implications.	Semin Thromb Hemost. 2006;32:577‐588.
	 7.	 Shetty	 S,	 Kasatkar	 P,	 Ghosh	 K.	 Pathophysiology	 of	 acquired	
von	 Willebrand	 disease:	 a	 concise	 review.	 Eur J Haematol. 
2011;87:99‐106.
	 8.	 van	Genderen	P,	Boertjes	RC,	van	Mourik	JA.	Quantitative	anal‐
ysis	 of	 von	 Willebrand	 factor	 and	 its	 propeptide	 in	 plasma	 in	
acquired	von	Willebrand	syndrome.	Thromb Haemostas. 1998;80: 
495‐498.
	 9.	 Haberichter	SL,	Balistreri	M,	Christopherson	P	et	al.	Assay	of	the	
von	Willebrand	factor	(VWF)	propeptide	to	identify	patients	with	
type	1	von	Willebrand	disease	with	decreased	VWF	survival.	Blood. 
2006;108:3344‐3351.
	10.	 Stufano	F,	Boscarino	M,	Bucciarelli	P	et	al.	Evaluation	of	the	Utility	
of	von	Willebrand	Factor	Propeptide	in	the	Differential	Diagnosis	
of	von	Willebrand	Disease	and	Acquired	von	Willebrand	Syndrome.	
Semin Thromb Hemost.	2018;10‐1660481.
	11.	 Franchi	F,	Biguzzi	E,	Stufano	F,	Siboni	SM,	Baronciani	L,	Peyvandi	
F.	A	two‐step	approach	(Enzyme‐linked	immunosorbent	assay	and	
confirmation	 assay)	 to	 detect	 antibodies	 against	 von	Willebrand	
factor	in	patients	with	Acquired	von	Willebrand	Syndrome.	Thromb 
Res.	2014;134:1316‐1322.
	12.	 Lee	A,	 Sinclair	 G,	 Valentine	 K,	 James	 P,	 Poon	MC.	 Acquired	 von	
Willebrand	 syndrome:	 von	 Willebrand	 factor	 propeptide	 to	 von	
Willebrand	 factor	 antigen	 ratio	 predicts	 remission	 status.	 Blood. 
2014;124:e1–e3ì.
Received:	13	March	2018  |  Revised:	22	September	2018  |  Accepted:	11	October	2018
DOI: 10.1111/hae.13630
Does haemophilia slow down the development of liver fibrosis?
Dear	Editor,
Haemophilia	 is	 an	 X‐linked	 recessive	 bleeding	 disorder,	 resulting	
from	deficient	or	dysfunctional	coagulation	factor	VIII	(haemophilia	
A)	or	IX	(haemophilia	B).	Depending	on	the	severity	of	their	factor	
deficiency,	patients	present	with	a	range	of	bleeding	diathesis	from	
traumatic	injury	or	surgically	induced	bleeding	to	spontaneous	hae‐
morrhage	in	the	soft	tissues,	joints	or	muscles.
Before	the	1960s,	the	prognosis	of	severe	haemophilia	A	patients	
was	just	11	years	or	less,1	then	the	introduction	of	fresh‐frozen	plasma,	
cryoprecipitate,	and	finally	blood‐pooled	clotting	factor	concentrates	
considerably	improved	the	survival	and	quality	of	life	of	patients	with	
haemophilia	or	with	other	bleeding	disorders.2	However,	the	epidemic	
of	HCV	and	human	immunodeficiency	virus	(HIV)	then	erupted	with	
severe	consequences.	Until	 the	1989	discovery	of	HCV,3	 almost	 all	
haemophilia	patients	 treated	with	clotting	 factor	products	were	 in‐
fected	with	HCV.4	The	clinical	presentation	of	HCV	is	characterized	
by	chronic	liver	disease	that	can	progress	to	fibrosis	with	development	
of	(de)compensated	cirrhosis	and	hepatocellular	carcinoma.
An	unexpected	new	finding	was	reported	by	Assy	et	al5	who	found	
that	 liver	disease	 following	HCV	 infection	 appeared	more	benign	 in	
haemophilia	subjects	than	in	others.	This	was	unexpected	considering	
that	HCV	infection	was	one	of	the	major	causes	of	mortality	in	patients	
with	haemophilia	before	the	introduction	of	direct	acting	antivirals.	The	
authors	investigated	the	histological	severity	of	liver	fibrosis	in	haemo‐
philia	 HCV‐infected	 patients	 compared	 with	 HCV‐infected	 patients	
with	 no	 bleeding	 disorder,	 demonstrating	 significantly	 lower	 histo‐
logic	inflammatory	activity	and	fibrosis	scores	in	patients	with	haemo‐
philia.	However,	the	small	scale	of	this	study	and	high	heterogeneity	
of	included	patients	render	it	difficult	to	establish	a	clear	link	between	
haemophilia	and	reduced	liver	damage	following	HCV	infection.
Haemophilia	A	murine	models	 that	mimic	patients	with	 severe	
haemophilia	 A	 are	 currently	 available.	 These	 well‐characterized	
models	 have	 been	 extensively	 employed	 to	 evaluate	 new	 treat‐
ments.6	In	this	report,	we	have	studied	the	progression	of	chemically	
induced	liver	fibrosis	by	means	of	an	haemophilia	A	mouse	model.
The	study	was	carried	out	using	12	control	mice	(=CTL	mice)	with	
normal	factor	VIII	 levels	 (8	weeks	old,	C57BL/6,	sourced	from	The	
Jackson	 Laboratory,	Bar	Harbor,	Maine,	USA)	 and	12	haemophilia	
mice	 (=HEMO	mice)	with	 factor	 VIII	 levels	 <1%	 (7	weeks	 old;	 B6;	
129S‐F8tm1Kaz/J,	sourced	from	The	Jackson	Laboratory).	Each	group	
was	 divided	 into	 subgroups	 receiving	 either	 thioacetamide	 (TAA)	
in	their	drinking	water	(200	mg	TAA/L;	CTL‐TAA,	and	HEMO‐TAA)	
or	only	water	without	TAA	(CTL‐H2O	and	HEMO‐H2O).	TAA	(pur‐
chased	 as	 white	 crystalline	 powder	 from	 Sigma‐Aldrich;	 St	 Louis,	
MO,	USA)	 is	 an	organosulfur	 compound	 that	 induces	 liver	 fibrosis	
while	being	water	soluble.	The	mice	were	housed	in	a	temperature‐
controlled	environment	(12‐hour	light	cycle)	with	food	and	water	ad	
libitum.	In	the	HEMO	groups,	mice	were	housed	individually	to	avoid	
injuries.	The	amount	of	water	the	mice	consumed	and	their	weight	
were	monitored	weekly	to	determine	the	exact	dose	of	TAA	admin‐
istered.	 After	 25	weeks,	 the	mice	 were	 sacrificed	 and	 their	 livers	
harvested.	Three	haemophilia	mice	died	unexpectedly	before	Week	
25	 due	 to	 external	 haemorrhages	 (two	 in	 the	HEMO‐H2O	 group;	
one	in	the	HEMO‐TAA	group)	and	were	excluded	from	analysis.
At	 the	 time	 of	 harvest,	 liver	 sections	were	 fixed	 in	 formalin	 and	
embedded	 in	 paraffin.	 Slices	were	 stained	with	PicroSirius	Red	 then	
